PVRI 2024 Annual Congress London

The next 50 years of pulmonary hypertension - a global view

Approved as compliant by the EthicalMedTech Conference Vetting System.
Accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 22 CME credits

Park Plaza London Riverbank, 18 Albert Embankment, London, SE1 7TJ
We look forward to welcoming you to our 16th Annual Congress

Programme highlights

PRE CONGRESS SATELLITE MEETING
Wednesday 31 January, City Suites, Ground Floor
09:00-17:00 Innovative Drug Development Initiative
09:00-17:05 Infection in PVD (IPVD) Consortium
12:00-18:40 Paediatric & Congenital Heart Disease Task Force

CLOSED MEETINGS, Park Suites, Mezzanine Level
Wednesday 31 January
08:30-17:00 Exercise Task Force
08:00-16:00 Latin American Task Force
08:30-13:30 Imaging Task Force
15:00-17:00 PVRI Board

Thursday, 1 February
12:20-13:30 Pulmonary Circulation Journal
13:00-14:00 History of PVD

MAIN SCIENTIFIC PROGRAMME, Ballroom, Level -2
Thursday 1 February
08:20-10:40 PH as a global health issue
11:00-12:20 Multiomics biology for deep phenotyping PVD
12:20-13:30 Lunch break
13:30-15:00 PVRI Task Force presentations
15:30-16:30 Featured abstracts
16:30-17:30 Poster presentations (Plaza Suites, Level -4)
17:30-18:00 PVRI General Meeting
18:00-19:30 Drinks reception (City Suites, Ground Floor)

Friday 2 February
08:30-10:10 The many faces of PH
10:35-12:20 Life of the pulmonary circulation - development, life cycle, and aging
12:20-13:30 Lunch break
12:20-13:30 Women in PH Luncheon sponsored by UTC (Executive Lounge, Level 12)
13:30-15:10 Clinical hot topics in PVD
15:30-16:30 Featured abstracts
16:30-18:00 Poster presentations (Plaza Suites, Level -4)
19:30-23:59 Gala dinner and awards presentation

Saturday 3 February
08:30-10:06 Therapeutic targets identification in PH
10:40-12:30 Novel therapeutics and clinical trial design
12:30-13:30 Lunch break
13:30-15:35 Providing effective care in low or middle income countries
16:00-17:15 Featured abstracts
17:15-17:30 Concluding remarks

POST CONGRESS SATELLITE MEETING, City Suites, Ground Floor
Sunday 4 February
09:30-14:30 PAH-ICON
Wednesday 31 January
Moderators: Raymond Benza, Peter Fernandes, Luke Howard, Sylvia Nikkho

09:00-09:05 PVRI’s President welcome
Kurt Stenmark

09:05-09:20 Introduction by IDDI Leaders and organisational changes
Sylvia Nikkho, Peter Fernandes, Raymond Benza, Luke Howard

REAL WORLD EVIDENCE - A JOINT SESSION WITH PVRI AND PHA USA

09:20-09:25 What are Real World Evidence (RWE) and Real World Data (RWD)? And what is its value?
Scott Visovatti and Athenais Boucly

09:25-09:35 What is the status of RWD and RWE in PH?
Steve Mathai

09:35-09:45 What are the challenges of obtaining RWD and RWE in PH? And what are the potential solutions to these challenges?
Jason Weatherald, Jean Elwing

09:45-09:55 What new resources are needed to provide a steady flow of meaningful RWD and RWE to the global PH community?
Kari Gillmeyer, Christian Gerges

09:55-10:20 Panel Discussion: What should PVRI do to address the need for RWD and RWE in 2024 and beyond?
Kellie Morland and Greg Elliott

10:20-10:35 REFRESHMENT BREAK

PAEDIATRIC CLINICAL TRIAL DESIGN & ENDPOINTS

10:35-10:45 Paediatric Clinical Trial Design & Endpoints Workstream update
Steve Abman, Sylvia Nikkho

10:45-11:00 Applying advances in genetics and biomarkers to enrich clinical research strategies in paediatric PH
Megan Griffiths, Eric Austin

11:00-11:05 Panel discussion, All speakers

ACCESS TO CARE

11:05-11:25 Access to Care survey
Franz Rischard

11:25-11:35 Panel discussion

PH GROUP III

11:35-11:55 Past, present & future
Steven Nathan, Sylvia Nikkho

11:55-12:05 Panel discussion, All speakers

12:05-12:35 LUNCH

NEW MODALITIES & TECHNOLOGIES FOR PH AND RHF

12:35-13:05 Innovation in inhalation therapy for PH: Insights on drugs under development for PH and their delivery characteristics
Nicholas Hill, Peter Fernandes

13:05-13:25 Compliance is more than following the rules. Treating PH with a medical device: Concept, clinical update, mechano-transduction
Marc Pritzker, John Scandura

13:25-13:55 Advances in hemodynamic monitoring:
(a) Virtual prognostication using implantable hemodynamic monitoring
(b) Personalised prognostication with Xenon MRI to assess microvascular hemodynamics
Raymond Benza, Harry Rowland, Bastiaan Driehuys

13:55-14:15 Panel discussion, All speakers

14:15-14:25 REFRESHMENT BREAK

PATIENT ENGAGEMENT & EMPOWERMENT

14:25-14:45 PH Global Patient Survey (PH GPS)
Joanna Pepke-Zaba, Joseph Newman, Matt Granato, Mark Toshner

14:45-14:55 Panel discussion, All speakers

CHALLENGES OF CLINICAL TRIAL DESIGN, CONDUCT & ENDPOINTS

14:55-15:05 Utility of the OLE study design in PAH drug development
Harm Jan Bogaard, CQ Deng

15:05-15:15 Utility of the win ratio analysis approach in PAH clinical trials
Harm Jan Bogaard, CQ Deng

15:15-15:25 Panel discussion, All speakers

LUNG TRANSPLANTATION IN PH

15:25-15:45 Overcoming access challenges to transplantation in PH
Laurent Savale

15:45-15:55 Panel discussion

IDDI CROSS-WORKSTREAM

15:55-17:00 IDDI Cross-workstream roundtable discussion
Raymond Benza, Peter Fernandes, Luke Howard, Sylvia Nikkho
**Wednesday 31 January**

09:00-09:05  Welcome & opening remarks  

Navneet Dhillon

Each talk includes a 5-10 minute discussion

**CURRENT UPDATES ON INFECTIONS ASSOCIATED WITH PVDs**

*Moderators: Vinicio de Jesus Perez, Brian Graham*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:05-09:25</td>
<td>Global etiology of infection and PVD: lessons from registries</td>
<td>Ana Olga Mocumbi</td>
</tr>
<tr>
<td>09:25-09:45</td>
<td>Prospective multicentre cohort study of COVID-19 outcomes in high</td>
<td>Peter Nyasulu</td>
</tr>
<tr>
<td></td>
<td>HIV and tuberculosis burden population</td>
<td></td>
</tr>
<tr>
<td>09:45-10:05</td>
<td>Post-tuberculosis PVD in South Africa</td>
<td>Friedrich Thienmann</td>
</tr>
<tr>
<td>10:05-10:25</td>
<td>Epidemiology of schistosomiasis and PH in Brazil</td>
<td>Camila Loureiro</td>
</tr>
<tr>
<td>10:25-10:45</td>
<td>Paracoccidioidomycosis-induced PH</td>
<td>Alexandre Fabro, Sabrina Batah</td>
</tr>
<tr>
<td>10:45-10:55</td>
<td>Panel discussion, All speakers</td>
<td></td>
</tr>
<tr>
<td>10:55-11:10</td>
<td>REFRESHMENT BREAK</td>
<td></td>
</tr>
</tbody>
</table>

**MECHANISTIC INSIGHTS ON HIV/SCHISTOSOMIASIS & PH**

*Moderators: Navneet Dhillon, Ana Olga Mocumbi*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:40-14:00</td>
<td>HIV/Emphysema and PH</td>
<td>Alison Morris</td>
</tr>
<tr>
<td>14:00-14:20</td>
<td>HIV and PAH: mechanistic insight</td>
<td>Sharilynn Almodovar</td>
</tr>
<tr>
<td>14:20-14:40</td>
<td>Inflammation and co-infection with schistosoma on PVD</td>
<td>Rahul Kumar</td>
</tr>
<tr>
<td>14:40-15:00</td>
<td>γδ T cells in the HIV and schistosoma pulmonary comorbidity: lessons from a non-infectious mouse model</td>
<td>Edgar Fernández-Malavé</td>
</tr>
<tr>
<td>15:00-15:20</td>
<td>Exercise intolerance in schistosomiasis associated PAH vs idiopathic PAH: mechanistic insights into differential pathophysiology underlying PAH etiologies</td>
<td>Rudolf Oliveira</td>
</tr>
<tr>
<td>15:20-15:35</td>
<td>REFRESHMENT BREAK</td>
<td></td>
</tr>
</tbody>
</table>

**MICROBIOME & PH**

*Moderators: Angel Cogolludo, Peter Nyasulu*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:35-15:55</td>
<td>Modulating the gut microbiome to treat PAH</td>
<td>Thenappan Thenappan</td>
</tr>
<tr>
<td>15:55-16:15</td>
<td>Lung microbiome changes in HIV</td>
<td>Homer L. Twigg III</td>
</tr>
<tr>
<td>16:15-16:35</td>
<td>Cardiopulmonary pathogenic networks: schistosoma-PAH and the lung microbiome</td>
<td>Suellen D'Arc Olivera</td>
</tr>
<tr>
<td>16:35-16:55</td>
<td>POST-COVID changes in the microbiome</td>
<td>Olga Tura</td>
</tr>
<tr>
<td>16:55-17:05</td>
<td>Closing remarks</td>
<td>Ghazwan Butrous</td>
</tr>
</tbody>
</table>

**COVID, CO-INFECTIONS & PVDs**

*Moderators: Sir Magdi Yacoub, Nicola Petrosillo*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:10-11:30</td>
<td>HIV/COVID-19 and pulmonary vascular injury</td>
<td>Navneet Dhillon</td>
</tr>
<tr>
<td>11:30-11:50</td>
<td>Long-haul COVID-19 and right ventricle dysfunction</td>
<td>Rudolf Oliveira</td>
</tr>
<tr>
<td>11:50-12:10</td>
<td>Cardio-pulmonary outcomes of schistosomiasis-infected patients in the post-COVID era</td>
<td>Brian Graham</td>
</tr>
<tr>
<td>12:10-12:30</td>
<td>Post-TB/PAH through the lens of South African cohort and animal models</td>
<td>Gerald Maarman</td>
</tr>
<tr>
<td>12:30-12:40</td>
<td>Panel discussion, All speakers</td>
<td></td>
</tr>
<tr>
<td>12:40-13:40</td>
<td>LUNCH BREAK</td>
<td></td>
</tr>
</tbody>
</table>
### Wednesday 31 January

**Joint session with PVRI Paediatric & Congenital Heart Disease Task Force, UK Paediatric Registry and Spanish Registry for Paediatric Pulmonary Hypertension (REHIPED)**

**12:00-12:35** An introduction and update of the PVRI Paediatric & Congenital Heart Disease Taskforce: history, goals, and activities  
*Shahin Moledina. Steven Abman, Maria Jesus del Cerro*

**12:35-13:10** LUNCH BREAK

---

**PAEDIATRIC PORTOPULMONARY HYPERTENSION**  
**Moderators:** Mary Mullen, Maria Jesus del Cerro

**13:10-13:25** Management of portopulmonary hypertension in Spain. Data from Rehiped registry  
*Alba Torrent-Vernetta*

**13:25-13:40** Management of portopulmonary hypertension in Argentina  
*Dora Haag*

**13:40-13:50** Panel discussion, All speakers

---

**PAEDIATRIC REGISTRIES & THEIR COLLABORATION**  
**Moderators:** Dunbar Ivy, Steven Abman

**13:50-14:05** UK registry for Paediatric PH  
*Shahin Moledina*

**14:05-14:15** Spanish registry for paediatric PH (REHIPED)  
*Maria Jesus del Cerro*

**14:15-14:30** Dutch registry  
*Rolf Berger*

**14:30-14:45** PPPHnet registry  
*Mary Mullen*

**14:45-14:55** Panel discussion, All speakers

---

**COLLABORATION BETWEEN REGISTRIES: EXAMPLES AND PROPOSALS**  
**Moderators:** Shahin Moledina, Allen Everett, Rolf Berger

**14:55-15:17** PPPHnet risk score for paediatric PH  
*(Includes a 10-minute discussion)*  
*Megan Griffiths*

**15:17-15:39** PK registry score for paediatric postoperative PH

---

**NEW RESEARCH ON PAEDIATRIC PH**  
**Moderators:** Rolf Berger, Usha Raj

**16:00-16:15** Comparing imaging, pathology, and hemodynamics of PH genetic syndromes in children  
*Mary Mullen*

**16:15-16:30** Pulmonary vein stenosis management at Boston Children’s Hospital  
*Kathy Jenkins*

**16:30-16:45** Right ventricular free wall strain in PH  
*Charles Simpkin*

**16:45-17:00** REFRESHMENT BREAK

**17:00-17:15** TRIPLE THERAPY in paediatric patients with PAH in a Latam centre  
*Humberto Garcia Aguilar*

**17:15-17:30** Fontan Kreutzer phenotype through multimodality imaging and cardiac catheterization  
*Emesto Juaned*

**17:30-17:45** Heart rate variability as prognostic marker in paediatric PH  
*Nikhil Sunil*

**17:45-18:00** What is new on RV failure management and VAD for pediatric PH?  
*Ryan Coleman*

**18:00-18:40** Prospects for the Paediatric & Congenital Heart Disease Task Force  
*Shahin Moledina. Steven Abman, Maria Jesus del Cerro*

**20:00** Dinner and get together for Paediatric & Congenital Heart Disease Task Force, UK Paediatric Registry, and REHIPED
Thursday 1 February

PH AS A GLOBAL HEALTH ISSUE
Moderators: Werner Seeger, Peter Nyasulu, Katrina Barry

08:20-08:25 PVRI President's welcome
Kurt Stenmark

08:25-08:40 The past and next 50 years of PH - a PVRI perspective
Paul Corris

08:40-08:45 What are the goals of the PVRI global health sessions?
Aaron Waxman

08:45-09:30 KEYNOTE: Conceptualising PH through a global health lens
Sue Goldie

09:30-09:45 What is included in "PH"?
Greg Elliott

09:45-10:00 What do we know (and not know) about the global epidemiology and burden of PH?
Ana Olga Mocumbi

10:00-10:15 What data sources are available to understand the GBD in PH?
Thenanppan Thenanppan

10:15-10:40 Panel discussion
All speakers

10:40-11:00 REFRESHMENT BREAK

MULTIOMICS BIOLOGY FOR DEEP PHENOTYPING PVD
Moderators: Sori Savai-Pullamsetti, Jane Leopold, Grazyna Kwapiszewska

11:00-11:20 KEYNOTE: Multi-omics approach to pathophenotype and precision therapeutics in PAH
Joseph Loscalzo

11:20-11:40 Platelet RNAs for the detection of cancer & PH
Myron Best

11:40-11:55 Creating a "digital twin" for evaluation & management of PAH
Pablo Lamata

11:55-12:20 Panel discussion
All speakers

12:20-13:30 LUNCH BREAK

12:20-13:30 Pulmonary Circulation Journal meeting

13:00-14:00 History of PVD meeting
**Friday 2 February**

### THE MANY FACES OF PH
**Moderators:** Ghazwan Butrous, Lucilla Piccari

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:00</td>
<td>Social determinants of health impact of broader context</td>
<td>Marion Delcroix</td>
</tr>
<tr>
<td>09:00-09:15</td>
<td>Africa – regional differences</td>
<td>Hanan Yusuf Ahmed</td>
</tr>
<tr>
<td>09:15-09:30</td>
<td>South America - regional differences</td>
<td>Mauricio Orozco-Levi</td>
</tr>
<tr>
<td>09:30-09:45</td>
<td>Asia - regional differences</td>
<td>Zhenguo Zhai</td>
</tr>
<tr>
<td>09:45-10:10</td>
<td>Panel discussion</td>
<td>All speakers</td>
</tr>
<tr>
<td>10:10-10:35</td>
<td>REFRESHMENT BREAK</td>
<td></td>
</tr>
</tbody>
</table>

### LIFE OF THE PULMONARY CIRCULATION -DEVELOPMENT, LIFE CYCLE, AND AGING
**Moderators:** Daniela Valdez-Jasso, Andrea Frump, Jason Elinoff

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:35-10:50</td>
<td>Role of TBX4 in neonatal and paediatric developmental lung disease</td>
<td>Eric Austin</td>
</tr>
<tr>
<td>10:50-11:10</td>
<td>KEYNOTE: Cardiac development and regeneration and their roles for right ventricular function in pulmonary vascular disease</td>
<td>Thomas Braun</td>
</tr>
<tr>
<td>11:10-11:30</td>
<td>KEYNOTE: Gene networks controlling PVD: Lessons from alveolar and acinar dysplasia</td>
<td>Jeffrey Whitsett</td>
</tr>
<tr>
<td>11:30-11:50</td>
<td>KEYNOTE: Vascular aging in the lung and systemic circulations</td>
<td>Anjali Kusumbe</td>
</tr>
<tr>
<td>11:50-12:20</td>
<td>Panel discussion</td>
<td>All speakers</td>
</tr>
<tr>
<td>12:20-13:30</td>
<td>LUNCH BREAK</td>
<td></td>
</tr>
</tbody>
</table>

### CLINICAL HOT TOPICS IN PVD
**Moderators:** Gustavo Heresi, Katarina Zeder, Karin Tran-Lundmark

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-13:42</td>
<td>Pulmonary embolism &amp; CTEPH: One disease with different phenotypes?</td>
<td>Gustavo Heresi</td>
</tr>
<tr>
<td>13:42-13:54</td>
<td>Take a deep breath: Inhalational therapies for Group 3 PH</td>
<td>Oksana Shlobin</td>
</tr>
<tr>
<td>13:54-14:06</td>
<td>SGLT2 inhibitors &amp; emerging therapies in HFpEF-PH</td>
<td>Lisa Mielenzuk</td>
</tr>
<tr>
<td>14:06-14:18</td>
<td>Activin signalling inhibitors in PAH</td>
<td>Marc Humbert</td>
</tr>
<tr>
<td>14:18-14:30</td>
<td>Building bridges: Shunts &amp; devices to support advanced PH</td>
<td>Alison Witkin</td>
</tr>
<tr>
<td>14:30-14:42</td>
<td>Not just little adults: Clinical update in paediatric PVD</td>
<td>Nidhy Varghese</td>
</tr>
<tr>
<td>14:42-15:02</td>
<td>Panel discussion</td>
<td>All speakers</td>
</tr>
<tr>
<td>15:02-15:30</td>
<td>REFRESHMENT BREAK</td>
<td></td>
</tr>
</tbody>
</table>

**Main programme**

**THEMES**
- GLOBAL HEALTH
- TRANSLATIONAL SCIENCE
- CLINICAL SCIENCE

Ballroom, Level -2

**08:30-09:00** Social determinants of health impact of broader context

Marion Delcroix

**09:00-09:15** Africa – regional differences

Hanan Yusuf Ahmed

**09:15-09:30** South America - regional differences

Mauricio Orozco-Levi

**09:30-09:45** Asia - regional differences

Zhenguo Zhai

**09:45-10:10** Panel discussion

All speakers

**10:10-10:35** REFRESHMENT BREAK

**10:35-10:50** Role of TBX4 in neonatal and paediatric developmental lung disease

Eric Austin

**10:50-11:10** KEYNOTE: Cardiac development and regeneration and their roles for right ventricular function in pulmonary vascular disease

Thomas Braun

**11:10-11:30** KEYNOTE: Gene networks controlling PVD: Lessons from alveolar and acinar dysplasia

Jeffrey Whitsett

**11:30-11:50** KEYNOTE: Vascular aging in the lung and systemic circulations

Anjali Kusumbe

**11:50-12:20** Panel discussion

All speakers

**12:20-13:30** LUNCH BREAK

**12:20-13:30** WOMEN IN PH LUNCHEON, Executive Lounge, Level 12

Sponsored by United Therapeutics Corporation

**13:30-13:42** Pulmonary embolism & CTEPH: One disease with different phenotypes?

(Generic) Discussion

**13:42-13:54** Take a deep breath: Inhalational therapies for Group 3 PH

(Generic) Discussion

**13:54-14:06** SGLT2 inhibitors & emerging therapies in HFpEF-PH

(Generic) Discussion

**14:06-14:18** Activin signalling inhibitors in PAH

(Generic) Discussion

**14:18-14:30** Building bridges: Shunts & devices to support advanced PH

(Generic) Discussion

**14:30-14:42** Not just little adults: Clinical update in paediatric PVD

(Generic) Discussion

**14:42-15:02** Panel discussion

All speakers

**15:02-15:30** REFRESHMENT BREAK

**15:30-16:30** FEATURED ORAL PRESENTATIONS: PH across the life cycle, global and environmental impacts on disease burden

For full details please see Featured Oral Presentations page

**16:30-18:00** POSTER PRESENTATIONS, Plaza Suites, Level -4

Facilitators: Ke Yuan, Rebecca Vanderpool, Farbod Rahaghi, George Alba

**19:30-00:00** GALA DINNER & AWARDS PRESENTATION

Rupert Swift Award

Butrous Foundation Award

PVRI Travel Awards

Certificates of Excellence

Lifetime Achievement Award
Saturday 3 February

**THERAPEUTIC TARGET IDENTIFICATION IN PH**
Moderators: Edda Spiekerkoetter, Lan Zhao, Christopher Rhodes

08:30-08:50 **KEYNOTE:** From 'omics to hypotheses – Insights from molecular phenotyping in complex diseases  
Kerstin Meyer

08:50-09:10 **KEYNOTE:** A primer on drug repositioning and repurposing strategies  
Steven Corsello

09:10-09:22 Beyond the clot: CTEPH pathobiology  
Sudarshan Rajagopal

09:22-09:34 "Liquid biopsies" during the course of PVD  
Corey E Ventetuolo

09:34-09:46 NEDD9 as a vascular fibrosis target  
Bradley Maron

09:46-10:06 Panel discussion  
All speakers

10:06-10:40 **REFRESHMENT BREAK**

**NOVEL THERAPEUTICS AND CLINICAL TRIAL DESIGN**
Moderators: Paul Yu, Anna Hemnes, Jasleen Minhas

10:40-11:00 Revisiting Imatinib for PAH: insights from remote monitoring  
Martin Wilkins

11:00-11:20 Acute & long COVID-19: Potential risk factor of PVD?  
Navneet Dhillon

11:20-11:40 The ins and outs of PDGF signalling as a therapeutic paradigm  
Sophie Nadaud

11:40-12:00 **KEYNOTE:** Adding flexibility to PH trials by implementing adaptive designs: overview of opportunities and challenges  
Sofia Villar

12:00-12:30 Panel discussion  
All speakers

12:30-13:30 **LUNCH BREAK**

**PROVIDING EFFECTIVE CARE IN LOW OR MIDDLE INCOME COUNTRIES**
Moderators: Ardeschir Ghofrani, Camila Loureiro

13:30-14:25 **KEYNOTE** Building high-value health systems: opportunities & challenges  
Rifat Atun

14:25-14:45 Global overview of diagnostics  
Jane Kabwe

14:45-15:05 Management and treatment options for low and middle-income countries  
Gil Golden

15:05-15:35 Panel discussion  
All speakers

15:35-16:00 **REFRESHMENT BREAK**

16:00-17:15 **FEATURED ORAL PRESENTATIONS:** Novel targets, treatments, trials, and tests for PH  
For full details please see Featured Oral Presentations page

17:15-17:30 Concluding remarks and EBAC evaluation  
Kurt Stenmark

Ballroom, Level -2
Featured oral presentations

Thursday 1 February

15:30-16:30  Featured abstracts: Research related to disease phenotyping, machine learning/artificial intelligence, and epidemiology
Moderators: Robert Szulcek, Thomas Bertero, Suellen Darc Oliveira, Soban Umar

15:30-15:45  Development and evaluation of a deep learning-based PH screening algorithm using a digital stethoscope
(Includes a 5-minute discussion)
Gaurav Choudhary

15:45-16:00  AI-powered quantification of microvascular remodeling: a novel marker for PH
(Includes a 5-minute discussion)
Pietro Nardelli

16:00-16:15  Risk stratification in PH follow-up: complex scoring systems versus pulmonary hemodynamics
(Includes a 5-minute discussion)
Athiththan Yogeswaran

16:15-16:30  The genetic epidemiology and the genotype-phenotype relation in paediatric PAH
(Includes a 5-minute discussion)
Yuan He

Friday 2 February

15:30-16:30  FEATURED ABSTRACTS: PH across the life cycle, global and environmental impacts on disease burden
Moderators: Imad Al Ghouleh, Darlene Kim, Shelsey Johnson, Christophe Guignabert

15:30-15:45  PH Global Patient Survey (PH GPS): preliminary results
(Includes a 5-minute discussion)
Joseph Newman

15:45-16:00  A global assessment of access to care for patients with PH
(Includes a 5-minute discussion)
Alexander Kantorovich

16:00-16:15  Screening patients with schistosomiasis associated hepatosplenic disease for PH in Ethiopia and Zambia
(Includes a 5-minute discussion)
Hanan Yusuf Ahmed

16:15-16:30  Decentralised clinical studies: an opportunity to reduce environmental impact with remote monitoring?
(Includes a 5-minute discussion)
Frances Varian

Saturday 3 February

16:00-17:15  FEATURED ABSTRACTS: Novel targets, treatments, trials, and tests for PH
Moderators: Neil Goldenberg, Nadine Al-Naamani, Andrew Sweatt, Harm Jan Bogaard

16:00-16:15  SOTERIA: A long-term follow-up study of sotatercept for PAH
(Includes a 5-minute discussion)
Ioana Preston

16:15-16:30  Effects of acetazolamide on sleep-disordered breathing in PVD
(Includes a 5-minute discussion)
Mona Lichtblau

16:30-16:45  Targeting the ATP Citrate Lyase as a potential therapy against vascular remodeling disease
(Includes a 5-minute discussion)
Charlotte Romanet

16:45-17:00  Reversal of inflammatory reprogramming at single cell resolution by vasodilator agents in PAH
(Includes a 5-minute discussion)
Anna Kirillova

17:00-17:15  Loss of pore-forming Gasdermin D protects against PAH
(Includes a 5-minute discussion)
Anna Foley

"The PVRI is all about collaboration. It's about communication."
### Sunday 4 February

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:05</td>
<td>Welcome</td>
</tr>
<tr>
<td>09:05-09:30</td>
<td>Integration of genetics and 'omics data into risk calculators</td>
</tr>
<tr>
<td>09:30-09:55</td>
<td>Deciphering the genetic basis of Systemic Sclerosis</td>
</tr>
<tr>
<td>09:55-10:20</td>
<td>Genetics of the right ventricle</td>
</tr>
<tr>
<td>10:20-10:45</td>
<td>Panel discussion: Opportunities for artificial intelligence in pulmonary vascular research</td>
</tr>
<tr>
<td></td>
<td>Moderator: Rebecca Verderpool</td>
</tr>
<tr>
<td></td>
<td>Panel: Dennis Wang, Andrew Sweatt, Khodr Tello</td>
</tr>
<tr>
<td>10:45-10:47</td>
<td>Rapid Fire Presentations</td>
</tr>
<tr>
<td>10:47-10:49</td>
<td>Seven additional patients with SOX17-related PAH &amp; review of the literature</td>
</tr>
<tr>
<td>10:49-11:30</td>
<td>Refreshment break (including poster viewing)</td>
</tr>
<tr>
<td>11:30-11:45</td>
<td>Abstract Presentations</td>
</tr>
<tr>
<td>11:45-12:00</td>
<td>Pulmonary vascular phenotype in patients with GDF2 (BMP9) or BMP10 variants: a multicentre study</td>
</tr>
<tr>
<td>12:00-12:15</td>
<td>SMAD6 as a possible cause of a congenital heart disease associated PAH</td>
</tr>
<tr>
<td>12:15-12:30</td>
<td>Phenotypic characterisation of SOX17-related PAH in children</td>
</tr>
<tr>
<td>12:30-12:45</td>
<td>Hereditary PAH – Genetics and environmental exposure untangled</td>
</tr>
<tr>
<td>12:45-13:35</td>
<td>Working Groups Lunch</td>
</tr>
<tr>
<td>13:35-14:25</td>
<td>Scleroderma genetics</td>
</tr>
<tr>
<td>14:25-14:30</td>
<td>Wrap up</td>
</tr>
</tbody>
</table>

**Rapid Fire Presentations**

- **Moderator**: Christina Eichstaedt
- 09:45-10:47: Seven additional patients with SOX17-related PAH & review of the literature
  - Natalia Gallego-Zazo
- 10:47-10:49: BMPR2 mutation and prognosis in PAH: a monocentric experience
  - Fabio Sirchia

**Abstract Presentations**

- 11:30-11:45: A rare case of PAH associated with a TBX4 mutation in a patient treated with dasatinib
  - Fabio Sirchia
- 11:45-12:00: Pulmonary vascular phenotype in patients with GDF2 (BMP9) or BMP10 variants: a multicentre study
  - Julien Grynblat
- 12:00-12:15: SMAD6 as a possible cause of a congenital heart disease associated PAH
  - Tina Eichstaedt
- 12:15-12:30: Phenotypic characterisation of SOX17-related PAH in children
  - Cara Morgan
- 12:30-12:45: Hereditary PAH – Genetics and environmental exposure untangled
  - Tina Eichstaedt

**Working Groups Lunch**

- 12:45-13:35: Multi-omics & artificial intelligence
  - Christopher Rhodes, Allan Lawrie
  - EIF2AK4 mutation carriers
  - David Montani
- 13:35-14:25: Scleroderma genetics
  - Paul Hassoun, Allan Lawrie
  - Healthy mutation carriers
  - Harm Jan Bogaard
- 14:25-14:30: Wrap up